Carbidopa/LevodopaThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

857 records returned

Transient gender-related effects in Parkinson’s disease patients with subthalamic stimulationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract Little is known about the gender-related long-term efficacy and safety after subthalamic nucleus deep brain stimulation (STN DBS) implant for Parkinson’s disease (PD), although some differences could be expected as recently stated in a short-term report. We assessed the possible gender-related differences in clinical outcome and disease progression along a 5-year period after STN DBS for PD. A prospective cohort of PD patients who underwent STN DBS and reached the 5-year follow-up (FU) was considered. Clinical outcome, disease progression and side effects were assessed at baseline and 1, 3, and 5&...
Source: Journal of Neurology - November 17, 2009 Category: Neurology Tags: Journal of Neurology Source Type: journals

Safety and tolerability of putaminal AADC gene therapy for Parkinson diseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: This study provides class IV evidence that bilateral intrastriatal infusion of adeno-associated viral type 2 vector containing the human AADC gene improves mean scores on the Unified Parkinson’s Disease Rating Scale by approximately 30% in the on and off states, but the surgical procedure may be associated with an increased risk of intracranial hemorrhage and self-limited headache. (Source: Neurology)
Source: Neurology - November 16, 2009 Category: Neurology Authors: Christine, C. W., Starr, P. A., Larson, P. S., Eberling, J. L., Jagust, W. J., Hawkins, R. A., VanBrocklin, H. F., Wright, J. F., Bankiewicz, K. S., Aminoff, M. J. Tags: PET, Parkinson's disease/Parkinsonism, Gene therapy ARTICLES Source Type: journals

Subthalamic Nucleus Deep Brain Stimulation Improves Saccades in Parkinson's DiseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions. These results demonstrate that STN DBS has differential effects on the parameters of visually guided and internally generated saccades. These effects may be mediated by the influence of STN DBS on cortical ocular motor areas, the basal ganglia, ocular motor loop, or downstream structures such as the brainstem saccade generating circuits. (Source: Neuromodulation)
Source: Neuromodulation - November 13, 2009 Category: Neurology Authors: Adrian P. Fawcett, Esther G. González, Elena Moro, Martin J. Steinbach, Andres M. Lozano, William D. Hutchison Source Type: journals

The dopaminergic neurons of the A11 system in RLS autopsy brains appear normalEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study found no significant difference between RLS or control cases on any measure used: TH (+) cell volume, fractional GFAP staining, or general histological examination. Nor was there histological indication of any significant inflammation or concurrent ongoing pathology in these RLS cases. The findings do not support the concept of dramatic cell loss or of a neurodegenerative process in the A11 hypothalamic region of patients with RLS. However, that does not exclude the possibility that the A11 system is involved in RLS symptoms. Changes at the cellular level in dopaminergic metabolism or at the distal synapse with ...
Source: Sleep Medicine - November 12, 2009 Category: Sleep Medicine Authors: Christopher J. Earley, Richard P. Allen, James R. Connor, Luigi Ferrucci, Juan Troncoso Tags: Brief Communications Source Type: journals

CARBIDOPA AND LEVODOPAtablet [Mylan Pharmaceuticals Inc.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Updated Date: Nov 12, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - November 12, 2009 Category: Drugs & Pharmacology Source Type: organizations

HIV-associated parkinsonism with levodopa-induced dyskinesia and response to highly-active antiretroviral therapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
No abstract. (Source: Movement Disorders)
Source: Movement Disorders - November 11, 2009 Category: Neurology Authors: Christopher Kobylecki, Monty A. Silverdale, Anoop Varma, Jeremy P.R. Dick, Mark W. Kellett Source Type: journals

Comparing bromocriptine effects with levodopa effects on bladder function in Parkinson's diseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
To evaluate the effects of bromocriptine on bladder function in Parkinson's disease (PD) patients and compare these effects with those of (L-dopa). We recruited 8 patients with PD. Urodynamic study (UDS) was performed before and 1 hour after administering 100 mg L-dopa/decarboxylase inhibitor (DCI) and 2.5 hours after administering 7.5 mg bromocriptine. After the bromocriptine administration, urinary urgency aggravated. UDS revealed a decreased bladder volume at which detrusor overactivity (DO) was initiated, a decreased bladder volume at first sensation of bladder filling (FSV) (P < 0.05), an increased maximum Watts Facto...
Source: Movement Disorders - November 11, 2009 Category: Neurology Authors: Tomoyuki Uchiyama, Ryuji Sakakibara, Tatsuya Yamamoto, Takashi Ito, M Chiharu Yamaguchi, Yusuke Awa, Masashi Yano, Mitsuru Yanagisawa, Makoto Kobayashi, Yoshinori Higuchi, Tomohiko Ichikawa, Tomonori Yamanishi, Takamichi Hattori, Satoshi Kuwabara Source Type: journals

Levodopa response in early Parkinson's diseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
To further characterize the short-term levodopa response in early PD, we performed a retrospective analysis of the ELLDOPA study which randomized 361 early PD subjects to placebo, levodopa 150, 300, or 600 mg/day. We evaluated change in UPDRS motor scores (UPDRSm) from baseline to weeks 9 and 24, and identified changes in UPDRSm that best discriminated treatment with levodopa from placebo. Linear regressions were used to determine associations between baseline characteristics and changes in UPDRSm. Mean percent improvement in UPDRSm in levodopa-treated subjects was greater than that for placebo-treated subjects (27.4% vs. ...
Source: Movement Disorders - November 11, 2009 Category: Neurology Authors: Robert A. Hauser, Peggy Auinger, David Oakes, on behalf of the Parkinson Study Group Source Type: journals

[Review] Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disordersEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Dopamine is an essential neurotransmitter for many brain functions, and its dysfunction has been implicated in both neurological and psychiatric disorders. Parkinson's disease is an archetypal disorder of dopamine dysfunction characterised by motor, cognitive, behavioural, and autonomic symptoms. While effective for motor symptoms, dopamine replacement therapy is associated not only with motor side-effects, such as levodopa-induced dyskinesia, but also behavioural side-effects such as impulse control disorders (eg, pathological gambling and shopping, binge eating, and hypersexuality), punding (ie, abnormal repetitive non-g...
Source: Lancet Neurology - November 9, 2009 Category: Neurology Authors: Valerie Voon, Pierre-Olivier Fernagut, Jeff Wickens, Christelle Baunez, Manuel Rodriguez, Nancy Pavon, Jorge L Juncos, José A Obeso, Erwan Bezard Tags: Review Source Type: journals

Effect of subthalamic deep brain stimulation on postural abnormality in Parkinson disease.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Postural abnormality in patients with PD could be ameliorated by STN DBS, and therefore surgery should be considered before irreversible spinal deformity develops. PMID: 19895200 [PubMed - as supplied by publisher] (Source: Journal of Neurosurgery)
Source: Journal of Neurosurgery - November 6, 2009 Category: Neurosurgery Authors: Umemura A, Oka Y, Ohkita K, Yamawaki T, Yamada K Tags: J Neurosurg Source Type: journals

Periodic leg movements and REM sleep without atonia in Parkinson's disease with camptocormiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Camptocormia (a flexion of the trunk that only appears when standing or walking) affects a minority of patients with Parkinson's disease (PD). As it responds poorly to levodopa and is associated with reduced midbrain and pons volume, it may result from non-dopaminergic, brainstem lesions. As several sleep abnormalities in PD also result from non-dopaminergic brainstem lesions, we monitored sleep in 24 non-demented PD patients with (n = 12) and without (n = 12) camptocormia and in 12 controls. Nearly half (42%) patients with camptocormia had abnormal periodic leg movement indices (>15/h), versus 17% patients without camptoc...
Source: Movement Disorders - November 4, 2009 Category: Neurology Authors: Sophie Lavault, Frederic Bloch, Jean-Luc Houeto, Eric Konofal, Marie-Laure Welter, Yves Agid, Isabelle Arnulf Source Type: journals

Longitudinal study of the levodopa motor response in Parkinson's disease: Relationship between cognitive decline and motor functionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this prospective study of 34 patients with Parkinson's disease (PD), measurements of the short duration levodopa motor response have been performed every 3 years in defined off states. The mean time from initiation of levodopa treatment was 14.8 years, and 17 patients survived to the latest assessment stage. Off phase motor function worsened at a yearly rate of 2.2% of the maximum disability score. The magnitude of the levodopa response is well preserved as the disease progresses, and patients who developed motor fluctuations maintained better on phase motor function than nonfluctuators (P = 0.01). Ten patients, of whom...
Source: Movement Disorders - November 4, 2009 Category: Neurology Authors: Jane E. Alty, Benjamin G. Clissold, Craig D. McColl, Katrina A. Reardon, Mark Shiff, Peter A. Kempster Source Type: journals

CARBIDOPA AND LEVODOPAtablet [Goldline Laboratories, Inc.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Updated Date: Nov 2, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - November 2, 2009 Category: Drugs & Pharmacology Source Type: organizations

Review paper Optimisation of treatment of Parkinson’s disease with levodopaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This article presents the major strategies for individualisation and optimisation of levodopa therapy. The relationship between pharmacokinetic and pharmacodynamic effects of levodopa is discussed. Pharmacokinetic parameters in different stages of Parkinson’s disease are interpreted. Moreover, the main differences in pharmacokinetics of levodopa formulations and routes of administration are presented. The authors also suggest methods to increase efficacy and safety of levodopa therapy in patients with Parkinson’s disease. (Source: Articles of Polish Journal of Neurology and Neurosurgery - TERMEDIA publishing house)
Source: Articles of Polish Journal of Neurology and Neurosurgery - TERMEDIA publishing house - October 30, 2009 Category: Neurosurgery Source Type: journals

Alleviation of off-period dystonia in Parkinson disease by a microlesion following subthalamic implantation.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions The author postulated that off-period dystonia alleviation may reflect both a microsubthalamotomy and micropallidotomy effect. They hypothesize, moreover, that the microlesion could play a role in the 6-month postoperative outcome. PMID: 19877801 [PubMed - as supplied by publisher] (Source: Journal of Neurosurgery)
Source: Journal of Neurosurgery - October 30, 2009 Category: Neurosurgery Authors: Derrey S, Lefaucheur R, Chastan N, Gérardin E, Hannequin D, Desbordes M, Maltête D Tags: J Neurosurg Source Type: journals

[Fifteen years history of Parkinson's disease in Spain (1963-1977). A personal recollection.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Parkinson's disease (PD) and movement disorders, currently one of the leading subspecialties among Spanish neurologists, raised only modest interest during the seventies. This is well reflected in Revista de Neurologia, the first journal entirely devoted to Neurology in Spain. Along five years (1973-1977) only 3% out of papers published were devoted to this subject. The functions of the basal ganglia were poorly known. PD was regarded as a disorder of muscular tone, rigidity playing a pivotal role to explain most, if not all, parkinsonian signs. 'Arteriosclerotic parkinsonism', whatever the symptoms might be, was appli...
Source: Revista de Neurologia - October 29, 2009 Category: Neurology Authors: Gimenez-Roldan S Tags: Rev Neurol Source Type: journals

Determination of related substances of levodopa including the R-enantiomer by CEEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A CE assay for the simultaneous determination of the impurities of levodopa listed in the European Pharmacopoeia including the (R)-enantiomer was developed and validated. The analysis was performed in a fused-silica capillary employing sulfated [beta]-cyclodextrin as chiral selector at an applied voltage of 20 kV and a temperature of 18°C. The optimized background electrolyte consisted of 0.1 M sodium phosphate buffer, pH 2.0, containing 6 mg/mL sulfated [beta]-cyclodextrin. L-phenylalanine was used as the internal standard. The assay was validated in the range of 0.1-1.0% for the impurities at a concentration of levodopa...
Source: Electrophoresis - October 28, 2009 Category: Biochemistry Authors: Sudaporn Wongwan, Manuela Hammitzsch-Wiedemann, Gerhard K. E. Scriba Source Type: journals

Serpentine tongue: A rare manifestation following initiation of levodopa therapy in a patient with Parkinson's diseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report an interesting observation in a patient with PD who developed abnormal movements involving only the tongue soon after the introduction of levodopa and responded well to substitution of levodopa with dopamine agonist. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - October 27, 2009 Category: Neurology Authors: D.K. Prashantha, Pramod Kumar Pal Tags: Letters to the Editor Source Type: journals

A Swedish family with de novo α-synuclein A53T mutation: Evidence for early cortical dysfunctionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: A de novo α-synuclein A53T (p.Ala53 Th; c.209G > A) mutation has been identified in a Swedish family with autosomal dominant Parkinson's disease (PD). Two affected individuals had early-onset (before 31 and 40 years), severe levodopa-responsive PD with prominent dysphasia, dysarthria, and cognitive decline. Longitudinal clinical follow-up, EEG, SPECT and CSF biomarker examinations suggested an underlying encephalopathy with cortical involvement. The mutated allele (c.209A) was present within a haplotype different from that shared among mutation carriers in the Italian (Contursi) and the Greek-American Family ...
Source: Parkinsonism and Related Disorders - October 27, 2009 Category: Neurology Authors: Andreas Puschmann, Owen A. Ross, Carles Vilariño-Güell, Sarah J. Lincoln, Jennifer M. Kachergus, Stephanie A. Cobb, Suzanne G. Lindquist, Jørgen E. Nielsen, Zbigniew K. Wszolek, Matthew Farrer, Håkan Widner, Danielle van Westen, Douglas Hägerström, Tags: Papers Source Type: journals

SINEMET (Carbidopa And Levodopa) Tablet, Extended Release [Bristol-Myers Squibb Pharma Company]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Updated Date: Oct 22, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - October 22, 2009 Category: Drugs & Pharmacology Source Type: organizations

Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primateEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
No abstract. (Source: Synapse)
Source: Synapse - October 21, 2009 Category: Neurology Authors: Monty A. Silverdale, Christopher Kobylecki, Penelope J. Hallett, Qin Li, Anthone W. Dunah, Paula Ravenscroft, Erwan Bezard, Jonathan M. Brotchie Source Type: journals

Mirapexin prolonged release tablets (pramipexole) - New FormulationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: Manufacturer notification, eMC (electronic Medicines Compendium) Area: Other Library Updates > SPC Changes New Formulation Mirapexin prolonged-release tablets are a once-a-day oral formulation of pramipexole. Mirapexin is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa. (Source: NeLM - SPC Changes)
Source: NeLM - SPC Changes - October 20, 2009 Category: Drugs & Pharmacology Source Type: organizations

Once daily Mirapexin® (pramipexole prolonged release) for Parkinson's disease launched in the UKEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: No information given Area: News Boehringer-Ingelheim has launched a prolonged-release (once-daily) formulation of pramipexole (Mirapexin®) for the treatment of the signs and symptoms of idiopathic Parkinson's disease, for use as monotherapy or in combination with levodopa. According to the press release, 84.5% of patients participating in a recent double-blind trial successfully switched to Mirapexin prolonged release overnight; the majority of these were able to switch at the same daily dose (no specific study details presented). Please see the attached press release for further information. (Source: NeLM - News)
Source: NeLM - News - October 19, 2009 Category: Drugs & Pharmacology Source Type: organizations

Levodopa/tolcapone: Hypersexuality treated with carbamazepine in an elderly patient: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - October 19, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Med Sci Monit 2009; 15(11):BR339-348 "The effect of memantine and levodopa/carbidopa on the responses of phrenic nerve-diaphragm preparations from aged rats"Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Memantine inhibits neuromuscular transmission in vitro and with in vivo treatment. LD/CD treatment enhances neuromuscular transmission. Clinical implications need further investigation. (Source: Medical Science Monitor)
Source: Medical Science Monitor - October 19, 2009 Category: Research Tags: Original article Source Type: journals

Novel mutation affecting the pterin-binding site of PTS gene and review of PTS mutations in Thai patients with 6-pyruvoyltetrahydropterin synthase deficiencyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, severe neurological impairment from BH4 deficiency could be prevented by newborn screening for HPA and proper metabolic management. However, pterin analysis for early diagnosis of BH4 deficiency is still not available in most developing countries. Content Type Journal ArticleCategory CASE REPORTDOI 10.1007/s10545-009-1221-xAuthors N. Vatanavicharn, Faculty of Medicine Siriraj Hospital Division of Medical Genetics, Department of Pediatrics 2 Prannok Road, Bangkoknoi Bangkok Thailand 10700C. Kuptanon, Faculty of Medicine Siriraj Hospital Division of Medical Genetics, Department of Pediatrics 2 Prannok Ro...
Source: Journal of Inherited Metabolic Disease - October 14, 2009 Category: Internal Medicine Tags: Journal of Inherited Metabolic Disease Source Type: journals

Gout chemical 'may help' Parkinon'sEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study involved 800 people participating in the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) randomised controlled trial. This two-year Canadian trial enrolled people with early Parkinson’s disease (without severe symptoms and not currently using medications; average age 62). It aimed to test the theory that long-term treatment with monoamine oxidase type B inhibitor deprenyl (selegiline hydrochloride) and/or the antioxidant alpha-tocopherol would delay the onset of disability. For the purposes of this study, the researchers took a pre-treatment blood sample from 774 of the participants to ...
Source: NHS News Feed - October 14, 2009 Category: Consumer Health News Tags: Neurology Source Type: news

Gout chemical 'may help' Parkinson'sEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study involved 800 people participating in the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) randomised controlled trial. This two-year Canadian trial enrolled people with early Parkinson’s disease (without severe symptoms and not currently using medications; average age 62). It aimed to test the theory that long-term treatment with monoamine oxidase type B inhibitor deprenyl (selegiline hydrochloride) and/or the antioxidant alpha-tocopherol would delay the onset of disability. Researchers took a pre-treatment blood sample from 774 of the participants to check urate levels, and a sample of ...
Source: NHS News Feed - October 14, 2009 Category: Consumer Health News Tags: Neurology Source Type: news

Boehringer Ingelheim receives approval from the European Commission for Mirapexin®/Sifrol® prolonged-release, once daily tablet for the treatment of Parkinson`s diseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Ingelheim/Germany, 14 October 2009 – Boehringer Ingelheim today announced that the Mirapexin®/Sifrol® (pramipexole) new prolonged-release, once daily tablet has been granted marketing authorisation by the European Commission in all EU/EEA*) countries for the treatment of early and advanced idiopathic Parkinson’s disease (PD). The approval was based on the submission of clinical trial results showing that the new formulation can offer an efficacy and safety profile comparable to the immediate release tablet taken three times daily.1-6 In addition to clinical trial results that confirm the important therapeutic bene...
Source: Boehringer Ingelheim RSS-Newsfeed - October 14, 2009 Category: Research Source Type: organizations

Boehringer Ingelheim receives approval from the European Commission for Mirapexin®/Sifrol® prolonged-release, once daily tablet for the treatment of Parkinson`s diseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Ingelheim/Germany, 14 October 2009 - Boehringer Ingelheim today announced that the Mirapexin®/Sifrol® (pramipexole) new prolonged-release, once daily tablet has been granted marketing authorisation by the European Commission in all EU/EEA*) countries for the treatment of early and advanced idiopathic Parkinson`s disease (PD). The approval was based on the submission of clinical trial results showing that the new formulation can offer an efficacy and safety profile comparable to the immediate release tablet taken three times daily.1-6 In addition to clinical trial results that confirm the important therapeutic be...
Source: Boehringer Ingelheim RSS-Newsfeed - October 14, 2009 Category: Research Source Type: organizations

ORIGINAL CONTRIBUTION: Urate as a Predictor of the Rate of Clinical Decline in Parkinson DiseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Higher serum and cerebrospinal fluid urate concentrations at baseline were associated with slower rates of clinical decline. The findings strengthen the link between urate concentration and PD and the rationale for considering central nervous system urate concentration elevation as a potential strategy to slow PD progression.Published online October 12, 2009 (doi:10.1001/archneurol.2009.247). (Source: Archives of Neurology)
Source: Archives of Neurology - October 12, 2009 Category: Neurology Authors: Ascherio, A., LeWitt, P. A., Xu, K., Eberly, S., Watts, A., Matson, W. R., Marras, C., Kieburtz, K., Rudolph, A., Bogdanov, M. B., Schwid, S. R., Tennis, M., Tanner, C. M., Beal, M. F., Lang, A. E., Oakes, D., Fahn, S., Shoulson, I., Schwarzschild, M. A., Tags: Neurology, Movement Disorders, Parkinson Disease/ Parkinsonian Disorders, Prognosis/ Outcomes Original Contribution Source Type: journals

Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease [Original Contribution]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Higher serum and cerebrospinal fluid urate concentrations at baseline were associated with slower rates of clinical decline. The findings strengthen the link between urate concentration and PD and the rationale for considering central nervous system urate concentration elevation as a potential strategy to slow PD progression.Published online October 12, 2009 (doi:10.1001/archneurol.2009.247). (Source: Archives of Neurology)
Source: Archives of Neurology - October 12, 2009 Category: Neurology Authors: Ascherio, A., LeWitt, P. A., Xu, K., Eberly, S., Watts, A., Matson, W. R., Marras, C., Kieburtz, K., Rudolph, A., Bogdanov, M. B., Schwid, S. R., Tennis, M., Tanner, C. M., Beal, M. F., Lang, A. E., Oakes, D., Fahn, S., Shoulson, I., Schwarzschild, M. A., Tags: Neurology, Movement Disorders, Parkinson Disease/ Parkinsonian Disorders, Prognosis/ Outcomes Original Contribution Source Type: journals

Dopaminergic Neuromodulation of Semantic Processing: A 4-T fMRI Study with LevodopaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
There is emerging evidence that alterations in dopaminergic transmission can influence semantic processing, yet the neural mechanisms involved are unknown. The influence of levodopa (L-DOPA) on semantic priming was investigated in healthy individuals (n = 20) using event-related functional magnetic resonance imaging with a randomized, double-blind crossover design. Critical prime–target pairs consisted of a lexical ambiguity prime and 1) a target related to the dominant meaning of the prime (e.g., bank–money), 2) a target related to the subordinate meaning (e.g., fence–sword), or 3) an unrelated target (e...
Source: Cerebral Cortex - October 7, 2009 Category: Neurology Authors: Copland, D. A., McMahon, K. L., Silburn, P. A., de Zubicaray, G. I. Tags: Articles Source Type: journals

The dopamine D2 receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with l-dopaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract Dopamine replacement therapy in Parkinson’s disease (PD) using l-dopa is invariably associated with a loss of drug efficacy (“wearing off”) and the onset of dyskinesia. The use of dopamine receptor partial agonists might improve therapeutic benefit without increased dyskinesia expression but may antagonise the effects of l-dopa. We now examine the effects of the novel high affinity, dopamine D2 receptor partial agonist, aplindore alone and in combination with l-dopa in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmoset. In non-dyskinetic MPTP treated animals, aplind...
Source: Journal of Neural Transmission - October 7, 2009 Category: Neurology Tags: Journal of Neural Transmission Source Type: journals

Short-Term Cost and Health Consequences of Duodenal Levodopa Infusion in Advanced Parkinsons Disease in Sweden: An Exploratory StudyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - October 6, 2009 Category: Health Management Authors: Kristiansen, Ivar SonboBingefors, KerstinNyholm, DagIsacson, Dag Tags: Original Research Articles Source Type: journals

The U937 macrophage cell line expresses enzymatically active l-Dopa decarboxylaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: In the present study we demonstrate that enzymatically active l-Dopa decarboxylase (DDC) is expressed in U937 cells, an important model of human macrophage function. The mRNA coding for the enzyme was found to be of the neural-type. DDC was detected in both the soluble and membrane fractions. The active molecule is released from the membrane fraction in the absence of detergent. Furthermore, exposure of U937 cells to carbidopa and dopamine considerably affected cell viability. The expression of enzymatically active DDC shows the endogenous production of dopamine in U937 cells and raises new questions about the en...
Source: Journal of Neuroimmunology - October 5, 2009 Category: Allergy & Immunology Authors: Ioanna Kokkinou, Emmanuel G. Fragoulis, Dido Vassilacopoulou Tags: Research Papers Source Type: journals

Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, the L-dopa nasal delivery system could be used as a good rescue therapy for PD patients who experience symptom fluctuation with oral L-dopa administration. PMID: 19804823 [PubMed - as supplied by publisher] (Source: European Journal of Pharmaceutical Sciences)
Source: European Journal of Pharmaceutical Sciences - October 1, 2009 Category: Drugs & Pharmacology Authors: Kim TK, Kang W, Chun IK, Oh SY, Lee YH, Gwak HS Tags: Eur J Pharm Sci Source Type: journals

Deal watch : Santhera licenses novel dyskinesia therapy to BiovailEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Deal watch : Santhera licenses novel dyskinesia therapy to Biovail Nature Reviews Drug Discovery 8, 762 (2009). doi:10.1038/nrd3009 Biovail Laboratories has signed an agreement with Santhera Pharmaceuticals, entitling Biovail to the US and Canadian rights to develop and commercialize fipamezole (also known as JP-1730), for the treatment of levodopa-induced dyskinesia in Parkinson's disease. The agreement involves an upfront payment of US$8 million from (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 1, 2009 Category: Drugs & Pharmacology Tags: News and Analysis Source Type: journals

Reduction of the postexcitatory cortical inhibition upon paired-click auditory stimulation in patients with Parkinson’s diseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Objectives: The aims of this study were: to investigate the postexcitatory inhibition of cortical evoked potentials on auditory paired-click stimulation in patients with Parkinson’s disease (PD), to analyze the correlation of N1–P2 amplitude ratios (A2/A1) with latency of the P300 auditory event-related potential and to determine the influence of Levodopa intake on postexcitatory inhibition and P300 latency.Methods: The central (Cz) auditory evoked potentials were recorded in 61 patients with PD and 21 age-matched healthy subjects.Results: Postexcitatory inhibition in auditory cortex in PD was significantly r...
Source: Clinical Neurophysiology - September 30, 2009 Category: Neuroscience Authors: E.P. Lukhanina, M.T. Kapustina, N.M. Berezetskaya, I.N. Karaban Tags: Original Research Articles Source Type: journals

Mylan Receives FDA Approval for Generic Version of Parkinson's Treatment Sinemet(R)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PITTSBURGH, Sept. 30 (HSMN NewsFeed) -- Mylan Inc. (Nasdaq: MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Ca... Biopharmaceuticals, Generics, Neurology, FDAMylan, Mylan Pharmaceuticals, Carbidopa, Levodopa, Sinemet (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 30, 2009 Category: Pharmaceuticals Source Type: news

Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We examined whether connecting both polymorphisms influences the effect of levodopa on Hcy. MTHFR genotypes and Hcy, vitamin B12, and folate levels were determined in 48 levodopa-treated PD patients (PD-L), 28 non-treated PD patients (PD-N) and 110 controls. Hcy was remarkably higher in PD-L than in PD-N and controls (p (Source: Journal of the Neurological Sciences)
Source: Journal of the Neurological Sciences - September 29, 2009 Category: Neurology Authors: Rey-Yue Yuan, Jau-Jiuan Sheu, Jia-Ming Yu, Chaur-Jong Hu, Ing-Jy Tseng, Chun-Sum Ho, Ching-Ying Yeh, Ya-Lin Hung, Tsuey-Ru Chiang Tags: Original Articles Source Type: journals

Impax Pharmaceuticals Reports Positive Results Of Phase II Trial Of IPX066, A Novel Formulation Of Carbidopa-Levodopa For Parkinson's DiseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ: IPXL) reported the positive results from a recently completed Phase II trial of its late-stage Parkinson's Disease drug candidate IPX066 In this cross-over trial, IPX066 reduced subjects' "off" time during waking hours by 2 hours compared to Sinemet (3.8 hours of "off" time for IPX066 vs. 5. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 23, 2009 Category: Consumer Health News Tags: Parkinson's Disease Source Type: news

Successful perioperative management of patients with Parkinson’s disease following gastrointestinal surgery: Report of three casesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This report presents the cases of three patients with Parkinson’s disease who underwent gastrointestinal surgery and had no serious postoperative complications. Antiparkinsonian medications were reduced before surgery and replaced by an intravenous infusion of levodopa until the patients could take oral antiparkinson drugs after surgery to prevent malignant syndrome or exacerbate parkinsonism. Prokinetics were also used for the prevention of paralytic ileus. These cases demonstrate an effective method to administer antiparkinson drugs during perioperative management of patients with Parkinson’s disease and also in...
Source: Surgery Today - September 23, 2009 Category: Surgery Tags: Surgery Today Source Type: journals

CARBIDOPA AND LEVODOPA Tablet CARBIDOPA AND LEVODOPA (Carbidopa And Levodopa) Tablet [Apotex Corp.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Updated Date: Sep 23, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - September 23, 2009 Category: Drugs & Pharmacology Source Type: organizations

Independent validation of the scales for outcomes in Parkinson's disease-autonomic (SCOPA-AUT)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Despite its heterogeneous content, which determines some weaknesses in the psychometric attributes of its subscales, SCOPA-AUT is an acceptable, consistent, valid and precise scale. (Source: European Journal of Neurology)
Source: European Journal of Neurology - September 22, 2009 Category: Neurology Authors: C. Rodriguez-Blazquez, M. J. Forjaz, B. Frades-Payo, J. de Pedro-Cuesta, P. Martinez-Martin Source Type: journals

Impax Pharmaceuticals Reports Positive Results of Phase II Trial of IPX066, a Novel Formulation of Carbidopa-Levodopa for Parkinson's DiseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
HAYWARD, Calif.--(BUSINESS WIRE)--Sep 21, 2009 - Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ: IPXL) today reported the positive results from a recently completed Phase II trial of its late-stage... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 22, 2009 Category: Pharmaceuticals Source Type: clinical trials

Apomorphine/levodopa: Psychiatric disorders: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - September 21, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Levodopa abuse, overdose: Dopamine dysregulation syndrome in an elderly patient: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - September 21, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Expression of catechol-O-methyltransferase in the brain and periphery of normal and MPTP-treated common marmosetsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract Catechol-O-methyltransferase (COMT) inhibition is widely used to potentiate the effects of levodopa in Parkinson’s disease but the effects of nigral dopaminergic cell loss and levodopa treatment on COMT activity are not known. The present study investigated the expression of COMT in the brain and liver of normal common marmosets, and animals treated with MPTP and those treated with levodopa to induce dyskinesia. Reverse transcript PCR demonstrated the expression of COMT mRNA in the liver, cortex and striatum of normal marmosets. Using Western blotting, the presence of two subunits of COMT protein,...
Source: Journal of Neural Transmission - September 21, 2009 Category: Neurology Tags: Journal of Neural Transmission Source Type: journals

Impax Pharmaceuticals Reports Positive Results of Phase II Trial of IPX066, a Novel Formulation of Carbidopa-Levodopa for Parkinson's DiseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Impax Pharmaceuticals,the brand products division of Impax Laboratories, Inc. (NASDAQ: IPXL) today reported the positive results from a recently completed Phase II trial of its late-stage Parkinson's Disease drug candidate IPX066. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - September 21, 2009 Category: Pharmaceuticals Source Type: news